Clinical Experience with α-Particle–Emitting (211)At: Treatment of Recurrent Brain Tumor Patients with (211)At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

α-Particle–emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system. Because of the much shorter range and more potent cytotoxicity of α-parti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Zalutsky, Michael R., Reardon, David A., Akabani, Gamal, Coleman, R. Edward, Friedman, Allan H., Friedman, Henry S., McLendon, Roger E., Wong, Terence Z., Bigner, Darell D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2007
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2832604/
https://ncbi.nlm.nih.gov/pubmed/18077533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.107.046938
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak